Literature DB >> 17220418

In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis.

James A Karlowsky, Nancy M Laing, Trish Baudry, Nachum Kaplan, David Vaughan, Daryl J Hoban, George G Zhanel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17220418      PMCID： PMC1855524          DOI： 10.1128/AAC.01254-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  7 in total

1.  Development of a Canadian standardized protocol for subtyping methicillin-resistant Staphylococcus aureus using pulsed-field gel electrophoresis.

Authors:  M R Mulvey; L Chui; J Ismail; L Louie; C Murphy; N Chang; M Alfa
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

2.  Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery.

Authors:  J W Campbell; J E Cronan
Journal:  Annu Rev Microbiol       Date:  2001       Impact factor: 15.500

3.  Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus.

Authors:  Duarte C Oliveira; Hermínia de Lencastre
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

Review 4.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

Review 5.  Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics.

Authors:  R J Heath; S W White; C O Rock
Journal:  Appl Microbiol Biotechnol       Date:  2002-03-07       Impact factor: 4.813

6.  Discovery of a novel and potent class of FabI-directed antibacterial agents.

Authors:  David J Payne; William H Miller; Valerie Berry; John Brosky; Walter J Burgess; Emile Chen; Walter E DeWolf; Andrew P Fosberry; Rebecca Greenwood; Martha S Head; Dirk A Heerding; Cheryl A Janson; Deborah D Jaworski; Paul M Keller; Peter J Manley; Terrance D Moore; Kenneth A Newlander; Stewart Pearson; Brian J Polizzi; Xiayang Qiu; Stephen F Rittenhouse; Courtney Slater-Radosti; Kevin L Salyers; Mark A Seefeld; Martin G Smyth; Dennis T Takata; Irene N Uzinskas; Kalindi Vaidya; Nicola G Wallis; Scott B Winram; Catherine C K Yuan; William F Huffman
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

7.  Community-associated methicillin-resistant Staphylococcus aureus, Canada.

Authors:  Michael R Mulvey; Laura MacDougall; Brenda Cholin; Greg Horsman; Melanie Fidyk; Shirley Woods
Journal:  Emerg Infect Dis       Date:  2005-06       Impact factor: 6.883
  7 in total
  23 in total

1.  Initial broth microdilution quality control guidelines for Debio 1452, a FabI inhibitor antimicrobial agent.

Authors:  James E Ross; Robert K Flamm; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

Review 2.  Antibacterial targets in fatty acid biosynthesis.

Authors:  H Tonie Wright; Kevin A Reynolds
Journal:  Curr Opin Microbiol       Date:  2007-08-17       Impact factor: 7.934

3.  Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI).

Authors:  Jiangwei Yao; John B Maxwell; Charles O Rock
Journal:  J Biol Chem       Date:  2013-11-04       Impact factor: 5.157

Review 4.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

Review 5.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

6.  Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252.

Authors:  Joshua B Parsons; Maciej Kukula; Pamela Jackson; Mark Pulse; Jerry W Simecka; David Valtierra; William J Weiss; Nachum Kaplan; Charles O Rock
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

7.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

8.  Design and synthesis of aryl ether inhibitors of the Bacillus anthracis enoyl-ACP reductase.

Authors:  Suresh K Tipparaju; Debbie C Mulhearn; Gary M Klein; Yufeng Chen; Subhasish Tapadar; Molly H Bishop; Shuo Yang; Juan Chen; Mahmood Ghassemi; Bernard D Santarsiero; James L Cook; Mary Johlfs; Andrew D Mesecar; Michael E Johnson; Alan P Kozikowski
Journal:  ChemMedChem       Date:  2008-08       Impact factor: 3.466

9.  Mechanism and inhibition of saFabI, the enoyl reductase from Staphylococcus aureus.

Authors:  Hua Xu; Todd J Sullivan; Jun-ichiro Sekiguchi; Teruo Kirikae; Iwao Ojima; Christopher F Stratton; Weimin Mao; Fernando L Rock; M R K Alley; Francis Johnson; Stephen G Walker; Peter J Tonge
Journal:  Biochemistry       Date:  2008-03-13       Impact factor: 3.162

10.  Design and synthesis of 2-pyridones as novel inhibitors of the Bacillus anthracis enoyl-ACP reductase.

Authors:  Suresh K Tipparaju; Sipak Joyasawal; Sara Forrester; Debbie C Mulhearn; Scott Pegan; Michael E Johnson; Andrew D Mesecar; Alan P Kozikowski
Journal:  Bioorg Med Chem Lett       Date:  2008-05-04       Impact factor: 2.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.